Nordic Bone

Dublin, 3 March 2014

Les Laboratoires Servier has terminated its licensing agreement with Osteologix for developing and commercializing NB S101 to treat post-menopausal osteoporosis, other bone and joint disorders and dental indications. As a result, Osteologix regains all rights to continue the development and commercialization of its improved formulation once day tablet of Strontium Succinate either independently or in collaboration with third parties. The company is currently assessing the most favorable way to move forward and will evaluate all options.

The board of directors